Ameliorative effect of yokukansan on vacuous chewing movement in haloperidol-induced rat tardive dyskinesia model and involvement of glutamatergic system

Brain Research Bulletin

Volumn 89, Issue 5-6, 2012, Pages 151-158

  Sekiguchi, Kyoji ^a   Kanno, Hitomi ^a   Yamaguchi, Takuji ^a   Ikarashi, Yasushi ^a   Kase, Yoshio ^a  

^a TSUMURA AND CO   (Japan)

Author keywords

Dopamine receptor; GLT 1; Glutamate; Haloperidol decanoate; Vacuous chewing movement; Yokukansan

Indexed keywords

GLUTAMATE TRANSPORTER; GLUTAMIC ACID; HALOPERIDOL DECANOATE; MESSENGER RNA; NATURAL PRODUCT; UNCLASSIFIED DRUG; YOKUKANSAN;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG EFFICACY; MASTICATION; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TARDIVE DYSKINESIA; TRADITIONAL MEDICINE; TREATMENT OUTCOME; VACUOUS CHEWING MOVEMENT;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; DYSKINESIA, DRUG-INDUCED; EXCITATORY AMINO ACID TRANSPORTER 2; GLUTAMIC ACID; HALOPERIDOL; HUMANS; MALE; MASTICATION; MOVEMENT; RATS; RATS, WISTAR; TREATMENT OUTCOME;

EID: 84867872596     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2012.08.008     Document Type: Article

References (52)

1. Adachi K., Hasegawa M., Fujita S., Sato M., Miwa Y., Ikeda H., Koshikawa N., Cools A.R. Dopaminergic and cholinergic stimulation of the ventrolateral striatum elicit rat jaw movements that are funnelled via distinct efferents. European Journal of Pharmacology 2002, 442:81-92.
2. Andreassen O.A., Aamo T.O., Jørgensen H.A. Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats. British Journal of Pharmacology 1996, 119:751-757.
3. Andreassen O.A., Jørgensen H.A. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia?. Progress in Neurobiology 2000, 61:525-541.
4. Bishnoi M., Boparai R.K. An animal model to study the molecular basis of tardive dyskinesia. Methods in Molecular Biology 2012, 829:193-201.
5. Blanchet P.J., Parent M.T., Rompré P.H., Lévesque D. Relevance of animal models to human tardive dyskinesia. Behavioral and Brain Functions 2012, 8:12.
6. Burger M.E., Fachineto R., Alves A., Callegari L., Rocha J.B. Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats. Brain Research 2005, 1031:202-210.
7. Daya R.P., Tan M.L., Sookram C.D., Skoblenick K., Mishra R.K. Alpha-phenyl-N-tert-butylnitrone prevents oxidative stress in a haloperidol-induced animal model of tardive dyskinesia: investigating the behavioural and biochemical changes. Brain Research 2011, 1412:28-36.
8. De Souza I.E., McBean G.J., Meredith G.E. Chronic haloperidol treatment impairs glutamate transport in the rat striatum. European Journal of Pharmacology 1999, 382:139-142.
9. Dearry A., Gingrich J.A., Falardeau P., Fremeau R.T., Bates M.D., Caron M.G. Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature 1990, 347:72-76.
10. Egashira N., Iwasaki K., Ishibashi A., Hayakawa K., Okuno R., Abe M., Uchida N., Mishima K., Takasaki K., Nishimura R., et al. Repeated administration of Yokukansan inhibits DOI-induced head-twitch response and decreases expression of 5-hydroxytryptamine (5-HT)2A receptors in the prefrontal cortex. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008, 32:1516-1520.
11. 3H]sulpiride binding in rat caudate-putamen: autoradiographic evidence for presynaptic D2 receptors on corticostriate terminals. Synapse 1988, 2:521-531.
12. Finkel S.I., Costa e Silva J., Cohen G., Miller S., Sartorius N. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. International Psychogeriatrics 1996, 8:497-500.
13. Fujiwara H., Takayama S., Iwasaki K., Tabuchi M., Yamaguchi T., Sekiguchi K., Ikarashi Y., Kudo Y., Kase Y., Arai H., et al. Yokukansan, a traditional Japanese medicine, ameliorates memory disturbance and abnormal social interaction with anti-aggregation effect of cerebral amyloid β proteins in amyloid precursor protein transgenic mice. Neuroscience 2011, 180:305-313.
14. Grandy D.K., Marchionni M.A., Makam H., Stofko R.E., Alfano M., Frothingham L., Fischer J.B., Burke-Howie K.J., Bunzow J.R., Server A.C., et al. Cloning of the cDNA and gene for a human D2 dopamine receptor. Proceedings of the National Academy of Sciences of the United States of America 1989, 86:9762-9766.
15. Hashimoto T., Ross D.E., Gao X.M., Medoff D.R., Tamminga C.A. Mixture in the distribution of haloperidol-induced oral dyskinesias in the rat supports an animal model of tardive dyskinesia. Psychopharmacology 1998, 137:107-112.
16. Hayes G., Biden T.J., Selbie L.A., Shine J. Structural subtypes of the dopamine D2 receptor are functionally distinct: expression of the cloned D2A and D2B subtypes in a heterologous cell line. Molecular Endocrinology 1992, 6:920-926.
17. Ikarashi Y., Iizuka S., Imamura S., Yamaguchi T., Sekiguchi K., Kanno H., Kawakami Z., Yuzurihara M., Kase Y., Takeda S. Effects of yokukansan, a traditional Japanese medicine, on memory disturbance and behavioral and psychological symptoms of dementia in thiamine-deficient rats. Biological and Pharmaceutical Bulletin 2009, 32:1701-1709.
18. Iwasaki K., Satoh-Nakagawa T., Maruyama M., Monma Y., Nemoto M., Tomita N., Tanji H., Fujiwara H., Seki T., Fujii M., et al. A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. Journal of Clinical Psychiatry 2005, 66:248-252.
19. Kamei J., Miyata S., Ohsawa M. Involvement of the benzodiazepine system in the anxiolytic-like effect of Yokukansan (Yi-gan san). Progress in Neuro-Psychopharmacology and Biological Psychiatry 2009, 33:1431-1437.
20. Kawakami Z., Kanno H., Ueki T., Terawaki K., Tabuchi M., Ikarashi Y., Kase Y. Neuroprotective effects of yokukansan, a traditional Japanese medicine, on glutamate-mediated excitotoxicity in cultured cells. Neuroscience 2009, 159:1397-1406.
21. Kawakami Z., Ikarashi Y., Kase Y. Isoliquiritigenin is a novel NMDA receptor antagonist in kampo medicine yokukansan. Cellular and Molecular Neurobiology 2011, 31:1203-1212.
22. Kawakami Z., Kanno H., Ikarashi Y., Kase Y. Yokukansan a kampo medicine, protects against glutamate cytotoxicity due to oxidative stress in PC12 cells. Journal of Ethnopharmacology 2011, 134:74-81.
23. Kegeles L.S., Abi-Dargham A., Frankle W.G., Gil R., Cooper T.B., Slifstein M., Hwang D.R., Huang Y., Haber S.N., Laruelle M. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Archives of General Psychiatry 2010, 67:231-239.
24. Konitsiotis S., Tsironis C., Kiortsis D.N., Evangelou A. Effects of N-methyl-d-aspartate receptor antagonism on neuroleptic-induced orofacial dyskinesias. Psychopharmacology 2006, 185:369-377.
25. Lee J., Son D., Lee P., Kim D.K., Shin M.C., Jang M.H., Kim C.J., Kim Y.S., Kim S.Y., Kim H. Protective effect of methanol extract of Uncaria rhynchophylla against excitotoxicity induced by N-methyl-d-aspartate in rat hippocampus. Journal of Pharmacological Sciences 2003, 92:70-73.
26. Liao J.F., Jan Y.M., Huang S.Y., Wang H.H., Yu L.L., Chen C.F. Evaluation with receptor binding assay on the water extracts of ten CNS-active Chinese herbal drugs. Proceedings of the National Science Council, Republic of China. Part B, Life Sciences 1995, 19:151-158.
27. Meshul C.K., Andreassen O.A., Allen C., Jørgensen H.A. Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol. Psychopharmacology 1996, 125:238-247.
28. Miyaoka T., Furuya M., Yasuda H., Hayashida M., Nishida A., Inagaki T., Horiguchi J. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008, 32:761-764.
29. Miyaoka T., Furuya M., Yasuda H., Hayashida M., Nishida A., Inagaki T., Horiguchi J. Yi-gan san as adjunctive therapy for treatment-resistant schizophrenia: an open-label study. Clinical Neuropharmacology 2009, 32:6-9.
30. Mizukami K., Asada T., Kinoshita T., Tanaka K., Sonohara K., Nakai R., Yamaguchi K., Hanyu H., Kanaya K., Takao T., et al. A randomized cross-over study of a traditional Japanese medicine (kampo) yokukansan, in the treatment of the behavioural and psychological symptoms of dementia. International Journal of Neuropsychopharmacology 2009, 11:1-9.
31. Nagaratnam N., Lewis-Jones M., Scott D., Palazzi L. Behavioral and psychiatric manifestations in dementia patients in a community: caregiver burden and outcome. Alzheimer Disease and Associated Disorders 1998, 12:330-334.
32. Naidu P.S., Singh A., Kulkarni S.K. Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms. British Journal of Pharmacology 2002, 136:193-200.
33. Nishi A., Yamaguchi T., Sekiguchi K., Imamura S., Tabuchi M., Kanno H., Nakai Y., Hashimoto K., Ikarashi Y., Kase Y. Geissoschizine methyl ether, an alkaloid in Uncaria hook, is a potent serotonin A receptor agonist and candidate for amelioration of aggressiveness and sociality by yokukansan. Neuroscience 2012, 207:124-136.
34. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, Sydney, Australia. 2nd ed.
35. Rowley H.L., Martin K.F., Marsden C.A. Determination of in vivo amino acid neurotransmitters by high-performance liquid chromatography with o-phthalaldehyde-sulphite derivatisation. Journal of Neuroscience Methods 1995, 57:93-99.
36. Sachdev P.S. The current status of tardive dyskinesia. Australian and New Zealand Journal of Psychiatry 2000, 34:355-369.
37. Schneider J.S., Wade T., Lidsky T.I. Chronic neuroleptic treatment alters expression of glial glutamate transporter GLT-1 mRNA in the striatum. Neuroreport 1998, 9:133-136.
38. Schwarcz R., Creese I., Coyle J.T., Snyder S.H. Dopamine receptors localised on cerebral cortical afferents to rat corpus striatum. Nature 1978, 271:766-768.
39. Sekiguchi K., Yamaguchi T., Tabuchi M., Ikarashi Y., Kase Y. Effects of yokukansan a traditional Japanese medicine, on aggressiveness induced by intracerebroventricular injection of amyloid beta protein into mice. Phytotherapy Research 2009, 23:1175-1181.
40. Sekiguchi K., Imamura S., Yamaguchi T., Tabuchi M., Kanno H., Terawaki K., Kase Y., Ikarashi Y. Effects of yokukansan and donepezil on learning disturbance and aggressiveness induced by intracerebroventricular injection of amyloid β protein in mice. Phytotherapy Research 2011, 25:501-507.
41. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990, 347:146-151.
42. Sunahara R.K., Guan H.C., O'Dowd B.F., Seeman P., Laurier L.G., Ng G., George S.R., Torchia J., Van Tol H.H., Niznik H.B. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 1991, 350:614-619.
43. Tabuchi M., Yamaguchi T., Iizuka S., Imamura S., Ikarashi Y., Kase Y. Ameliorative effects of yokukansan, a traditional Japanese medicine, on learning and non-cognitive disturbances in the Tg2576 mouse model of Alzheimer's disease. Journal of Ethnopharmacology 2009, 122:157-162.
44. Takeda A., Itoh H., Tamano H., Yuzurihara M., Oku N. Suppressive effect of Yokukansan on excessive release of glutamate and aspartate in the hippocampus of zinc-deficient rats. Nutritional Neuroscience 2008, 11:41-46.
45. Takeda A., Tamano H., Itoh H., Oku N. Attenuation of abnormal glutamate release in zinc deficiency by zinc and yokukansan. Neurochemistry International 2008, 53:230-235.
46. Takeda A., Iwaki H., Ide K., Tamano H., Oku N. Therapeutic effect of Yokukansan on social isolation-induced aggressive behavior of zinc-deficient and pair-fed mice. Brain Research Bulletin 2012, 87:551-555.
47. Tamano H., Kan F., Oku N., Takeda A. Ameliorative effect of Yokukansan on social isolation-induced aggressive behavior of zinc-deficient young mice. Brain Research Bulletin 2010, 83:351-355.
48. Tanji H., Ootsuki M., Matsui T., Maruyama M., Nemoto M., Tomita N., Seki T., Iwasaki K., Arai H., Sasaki H. Dementia caregiver's burdens and use of public services. Geriatrics and Gerontology International 2005, 5:94-98.
49. Tsai G., Goff D.C., Chang R.W., Flood J., Baer L., Coyle J.T. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. American Journal of Psychiatry 1998, 155:1207-1213.
50. Turrone P., Remington G., Kapur S., Nobrega J.N. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. Psychopharmacology 2003, 165:166-171.
51. Van Tol H.H., Bunzow J.R., Guan H.C., Sunahara R.K., Seeman P., Niznik H.B., Civelli O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991, 350:610-614.
52. Yamamoto B.K., Cooperman M.A. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. Journal of Neuroscience 1994, 14:4159-4166.